Project Grant R01CA287205
Award Date
8/9/24
Completion Date
7/31/29
Dollars Obligated
$596K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
This federal Project Grant award of $644,622 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) aims to enhance radioligand therapy for prostate cancer through the development of biomarker and dosimetry-guided personalized treatment approaches. The key objectives are to: 1) develop a novel method for bone marrow dosimetry using macro/micro Monte Carlo modeling, 2) build predictive models to estimate absorbed radiation doses from pre-therapy PET...
The National Cancer Institute (NCI) awarded a $1,003,173 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Radiopharmaceutical Imaging and Dosimetry, LLC to develop a prototype web/cloud-based quantitative SPECT reconstruction software system for clinical trials and dosimetry of radiopharmaceutical therapy (RPT) using alpha-emitting radionuclides. The key objectives are to: 1) improve existing quantitative SPECT methods by enhancing scatter and downscatter modeling and adding partial...
The National Cancer Institute (NCI) awarded a $671,072 Project Grant under CFDA 93.394 (Cancer Detection and Diagnosis Research) to the University of Washington (UW) to develop a novel ultra-miniaturized device termed "Picoliter Thin-Layer Chromatography (PTLC)" for high-throughput and sensitive analysis of lipid signaling in single cells from patient samples. This 5-year award, effective April 1, 2025, will leverage micro- and nano-fabrication techniques to create an easy-to-use,...
The National Cancer Institute (NCI) awarded a $898,497 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to Radiopharmaceutical Imaging and Dosimetry, LLC to develop a cloud-based, customer-responsive dosimetry tool for alpha-particle emitting radiopharmaceutical therapies. The key objectives are to: 1) establish a library of microscale S-values and apportionment factors for dose-limiting tissues, 2) implement a macro-to-micro dosimetry methodology to enable...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $602,361 to Yale University to develop deep learning-based predictive models for personalizing dosimetry and treatment planning for prostate cancer patients receiving 177Lu-PSMA radiopharmaceutical therapy (RPT). The key products and services to be delivered include: Building predictive models using pre-treatment PSMA-PET and during-treatment PSMA-SPECT imaging data, as well as clinical...
The National Cancer Institute (NCI) awarded Oncotab, Inc. a $400,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop an optimized targeted radiotherapy for pancreatic ductal adenocarcinoma (PDAC). Oncotab, Inc. will conduct a structured design of experiments to evaluate the use of a humanized tumor-associated MUC1 (TMUC1) antibody, as well as a tandem single-chain variable fragment (scFv) construct, labeled with alpha and beta particle-emitting radioisotopes....
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,237,513 to The Washington University to develop a novel combination molecular radiotherapy approach for treating relapsed and refractory neuroblastoma, the most common extracranial solid cancer in children. The research aims to evaluate the efficacy and biological effects of two high linear energy transfer radiopharmaceuticals, 77Br-MBBG targeting the norepinephrine transporter and...
This Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) will provide $159,636 to the University of Wisconsin-Madison over 5 years starting August 1, 2024. The purpose of the award is to support the development of a translational research program led by Dr. Quaovi Sodji that investigates using low-dose targeted radionuclide therapy (TRT) to enhance the efficacy of chimeric antigen receptor (CAR) T cell therapy against neuroblastoma, a deadly...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,283,068 to Washington University to develop and evaluate next-generation radioimmunotherapies for non-Hodgkin lymphoma. The 5-year project aims to create precision radiopharmaceutical therapies using single-agent and combination regimens of B-particle (Lu177) and A-particle (Ac225, Pb212, Th227) emitting anti-CD20 antibodies in preclinical models. It will also assess a...
This Project Grant award of $676,567.00 was provided by the National Cancer Institute (NCI), under the federal Cancer Treatment Research program (CFDA 93.395), to The Regents of the University of California, San Francisco (UCSF). The award will fund a multi-year research project to systematically test a transforming growth factor beta (TGFB) targeted theranostic radiopharmaceutical therapy approach across preclinical cancer models. The research aims to assess the biological effectiveness of...